Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 16 Genitourinary 10 Head & Neck 5 Gastrointestinal 5 Thoracic 4 Plasma cell 4 Other 4 Lymphoid 4 Gynecologic 3 Dermatologic 3 Other hematologic neoplasm 2 Tumor-Agnostic 1 Sarcoma 1 Other solid neoplasm 1 Other neoplasm 1 Myeloid 1 Classical hematology 1 CNS 1

Conditions

Interventions

Radiotherapy 220 Doxorubicin 210 Cyclophosphamide 210 Temozolomide 182 Ifosfamide 121 Filgrastim 111 Imatinib Mesylate 104 Etoposide 101 Vincristine 92 Gemcitabine 89 Bevacizumab 83 Magnetic Resonance Spectroscopy 80 Irinotecan 79 pembrolizumab 75 Radiation 69 Carboplatin 65 Methotrexate 62 pazopanib 61 Nivolumab 58 Cisplatin 58 fludarabine phosphate 57 Peripheral Blood Stem Cell Transplantation 57 Surgical Procedures, Operative 56 Specimen Handling 56 Trabectedin 52 Docetaxel 50 Biopsy 50 Busulfan 49 Melphalan 46 Paclitaxel 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sugars × Sarcoma × Clear all

NCT02606461 2023-01-23

SEAL

Karyopharm Therapeutics Inc

Phase 2/3 Completed

342 enrolled 36 charts

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡